Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways by Filho, Roberto Parise et al.
*Correspondence: R. Parise Filho. Department of Pharmacy, Center for 
Health and Biological Sciences, Mackenzie Presbyterian University. Rua da 
Consolação, 930 – Consolação – 01302-907 – São Paulo – SP, Brasil. E-mail: 
parisi@mackenzie.br
R
ev
ie
w
Brazilian Journal of 
Pharmaceutical Sciences
vol. 46, n. 3, jul./set., 2010
Prodrugs available on the Brazilian pharmaceutical market and 
their corresponding bioactivation pathways
Roberto Parise Filho1*, Michelle Carneiro Polli2, Silvio Barberato Filho3, Monique Garcia1, 
Elizabeth Igne Ferreira4
1Department of Pharmacy, Center for Health and Biological Sciences, Mackenzie Presbyterian University, 2Department of 
Pharmacy, São Francisco University, 3Department of Pharmacy, Sorocaba University, 4Department of Pharmacy, Faculty of 
Pharmaceutical Sciences, University of São Paulo
The aim of this paper was to emphasize the importance of prodrug design to therapy, by examining 
examples available on the Brazilian pharmaceutical market. The principles of prodrug design are briefly 
discussed herein. Examples of prodrugs from many important therapeutic classes are shown and their 
advantages relative to the drugs they are derived from are also discussed. Considering the importance of 
these therapeutic classes, from both therapy and economic standpoints, prodrug design is a very valuable 
aspect in the research of new drugs and for the pharmaceutical industry as a whole.
Uniterms: Prodrug design. Molecular modification. Drug development.
O objetivo do trabalho foi ressaltar a importância do planejamento de pró-fármacos para a terapia, 
por meio de exemplos disponíveis no mercado farmacêutico brasileiro. Os princípios da latenciação 
são sucintamente discutidos. Apresentam-se exemplos de pró-fármacos de muitas classes terapêuticas 
importantes e as vantagens relativas aos fármacos dos quais derivam são, também, discutidas. 
Considerando-se a importância dessas classes terapêuticas, tanto do aspecto terapêutico quanto do 
econômico, o planejamento de pró-fármacos representa aspecto de grande valor na busca de novos 
fármacos e na indústria farmacêutica como um todo.
Uniterms: Pró-fármacos/planejamento Fármacos/latenciação. Modificação molecular. Fármacos/
desenvolvimento.
INTRODUCTION
Currently, several tools are available for researching 
chemical entities aimed at introducing new pharmaceu-
ticals for use in therapy. Among the different strategies 
employed, molecular modification deserves special 
mention. This approach entails the structural alteration 
of a known and previously characterized lead compound. 
The starting molecule is called a prototype, whilst the 
derivatives obtained from the prototype are classified as 
either analogues or prodrugs, depending on the type of 
molecular modification executed. Molecular modification 
can have different aims with the main objectives being: 
the acquisition of substances with superior pharmaceu-
tical properties compared to those of the prototype, the 
discovery of a pharmacophoric group, or the study of the 
relationship between a chemical structure of a compound 
and its biological activity (Korolkovas, Burckhalter, 1988; 
Patani, Lavoie, 1996; Wermuth, 2006).
The molecular modification strategy is widely em-
ployed in the research and development of new drugs. 
Considering that this strategy involves use of a compound 
with previously known biological activity, the biological 
experiments to be executed with the new derivatives con-
sist of routine, and hence less complex, studies. Molecular 
modification enables the optimization of compounds that 
have previously been marketed and have presented phar-
macokinetic or toxicity issues. Furthermore, it is important 
to mention that the rate of success in the acquisition of a 
new chemical entity is greater when the structure of a pro-
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totype with a proven biological property is used (Ettmayer 
et al., 2004; Barreiro, Fraga, 2008).
As mentioned previously, molecular modification 
may give rise to compounds called prodrugs. This process 
is known as drug latentiation (Figure 1). 
Latentiation may be defined as the chemical union 
between a drug and a “transporter group”, normally by 
means of a covalent labile bond, giving rise to the clas-
sical concept of a prodrug. It is a temporarily inactive 
compound that, once inside the organism, needs to be 
metabolized to attain its active form (Bundgaard, 1985; 
Bundgaard, 1991; Chung et al., 2005; Liederer, Borchardt, 
2006; Parise-Filho et al., 2007; Rautio et al., 2008; Silva 
et al., 2005; Stella, 2004; Wermuth, 2006).
The term latentiation was first used to describe inacti-
ve compounds that required biotransformation before they 
could carry out their biological function (Albert, 1958; 
Harper, 1959). The compounds covered by this designation, 
known as prodrugs, are inactive by nature, and as such 
are not designed to function (Stella et al., 1985). Some 
long-known compounds provide examples of prodrugs, 
notwithstanding the fact that they were discovered before 
the concept of latentiation. One such example is codeine 
(Figure 2), isolated in the 19th Century. It was observed 
that this compound was converted into morphine when 
administered in vivo (Ettmayer et al., 2004; Santos, 2008).
In 1897, Felix Hoffmann employed the latentiation 
principal when he modified the structure of salicylic 
acid and obtained acetylsalicylic acid (Figure 3), with 
the aim of reducing its irritating effects on the stomach 
(Chung, Ferreira, 1998). However, it is known that ace-
tylsalicylic acid acts per se, on cyclooxygenases 1 and 2 
by means of acylation, as well as being active after the 
release of salicylic acid, whose properties are analogous 
to its derivative. It could therefore be considered a hybrid 
analogue-prodrug structure, like some other examples 
used in therapy. 
It was only from the 1970s onwards that the concept 
emerged of designing prodrugs to modify the non-ideal 
physical-chemical properties of certain compounds, thus 
making them more efficient (Stella, Nti-Addae, 2007). 
Accordingly, the latentiation method has since been em-
ployed by pharmaceutical chemists in the development 
of pharmaceuticals because it enables the improvement 
of several undesirable properties of a prototype without 
however, altering its biological effectiveness (Han, Ami-
don, 2000; Wermuth, 2006).
Because it causes changes in physical-chemical 
properties, the latentiation method is usually employed to 
resolve issues pertaining to the transport of drugs within 
the organism, whether by increasing their rate of absorp-
tion through cellular barriers, regulating their retention 
time within the organism (Han, Amidon, 2000; Shan et al., 
1997; Wermuth, 1984) or even by directing the drug to a 
specific location, a situation in which they are classified 
as directed drugs. These are highly selective latent types, 
FIGURE 1 - Diagram of the latentiation process. (D: drug, 
T: transporter group, D-T: prodrug) Adapted from Friis and 
Bundgaard(1996).
FIGURE 2 - Biotransformation of codeine, with the consequent 
release of morphine in vivo.
FIGURE 3 - Reaction of salicylic acid with acetic anhydride for the acquisition of acetylsalicylic acid and the release of acetic acid 
(the principal of latentiation).
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and form the basis of advanced forms of drug transporters 
(Chung et al., 2005; Silva et al., 2005). Based on these 
facts, the first step in latentiation comprises establishing 
the nature of the problem the drug presents. Such pro-
blems include: (1) instability or inadequate solubility in 
the formulation or when in contact with gastrointestinal 
fluids; (2) undesirable organoleptic characteristics; (3) 
inadequate hydrolipophilic equilibrium to pass through 
biological membranes, thus leading to a reduction in 
the rate of absorption; (4) drug toxicity; (5) high rate of 
biotransformation or pre-systemic elimination; (6) low 
functional specificity (Blau et al., 2006; Chung et al., 
2005; Silva et al., 2005; Taylor, 1996). Consequently, the 
purpose of designing a prodrug is to provide solutions to 
all the above-mentioned problems.
The examples in Figure 4 illustrate cases in which it 
was possible to design prodrugs to resolve inherent issues 
in some drugs.
The first example shows an increase in the liposo-
lubility of an antimalarial drug by replacing the carbonyl 
group with the methoxy group. In this case, the increase 
in liposolubility facilitates the passage of the drug through 
FIGURE 4 - Examples of prodrugs and their respective purposes.
the blood-brain barrier, thus making it useful in the treat-
ment of cerebral malaria. The next drug, haloperidol, had 
its hydroxyl masked by the formation of an ester bond with 
decanoic acid, giving a consequential increase in liposo-
lubility. This alteration in solubility led to the acquisition 
of a longer-acting, intra-muscularly applied, haloperidol 
derivative that releases the drug gradually into the orga-
nism. In the next example, chloranfenicol was esterified, 
by means of its primary hydroxyl group, upon reaction 
with palmitic acid, also resulting in increased liposolubi-
lity. Thus, the alteration in solubility of chloramphenicol 
reduced the dissolution of the drug in patients’ mouths, 
hence masking its bitter flavor (Chung et al., 2005).
Latentiation as a method of developing new drugs 
has been attracting increasing interest (Testa, 2004). In 
1985, Stella et al., questioned whether prodrugs presented 
any advantages in clinical practice. Six years later, in 1991, 
Hiller answered this question: 20% to 30% of drugs intro-
duced into therapy between 1986 and 1991 were developed 
with the latentiation method. More recent data indicates 
that approximately 15% of new drugs approved during the 
2001-02 period comprised prodrugs (Rautio et al., 2008).
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Considering the importance of molecular modifica-
tion of drugs as a source for the acquisition of new com-
pounds and given that the latentiation of drugs is an impor-
tant tool for this modification, this study aimed to prove, 
by means of the prodrugs available for use in therapy in 
Brazil, the real value of this process in the introduction 
of new drugs into clinical medicine. This review is based 
on the classification proposed by Wermuth (1984), which 
proposes the classification of latent forms into prodrugs 
and directed drugs. Wermuth classified the former into the 
following categories: classic, bioprecursors, reciprocal and 
mixed. The prodrugs, in their different categories, are the 
main focus of this study.
PRODRUGS IN THERAPY
Bioprecursors
Bioprecursors are latent forms that require biotrans-
formation, generally by means of oxy-reduction mechanis-
ms, with the aim of producing an active metabolite. These 
are compounds without a transporter group and several 
examples of prodrugs available for use in therapy in Brazil 
are classified as bioprecursors (Ettmayer et al., 2004).
Antivirals
Acyclovir, marketed under several pharmaceutical 
brandnames (Carneiro França, 2008), is a nucleoside 
analogue with an inhibiting function against the human 
herpes virus, including Herpes simplex (VHs) virus, types 
1 and 2, Varicella zoster (VVZ) virus, Epstein Barr (VEB) 
virus and cytomegalovirus (CMV). It was discovered by 
triage and introduced onto the market in 1981. It represents 
an evolution in the treatment of herpes, as it was the first 
relatively safe and non-toxic drug to be used systemically 
(Ettmayer et al., 2004; Patrick, 2005). In infected cells, 
the agent undergoes phosphorylation in three stages, thus 
generating an active triphosphate compound. Because it 
requires oxidative bioactivation, acyclovir is considered 
a bioprecursor prodrug. Figure 5 illustrates the mono-, 
bi- and triphosphorylation stages of acyclovir.
It is important to emphasize that acyclovir only 
undergoes triphosphorylation in infected cells. It more 
readily undergoes first step phosphorylation with viral 
thymidine kinase (100 x) than by the same enzyme in 
non-infected cells. Therefore, in normal cells, acyclovir 
is a poor substrate for cellular thymidine kinase, as it does 
not become active for these cells. This, together with the 
fact that selective capturing of acyclovir by infected cells 
occurs, explains its excellent effectiveness and low toxi-
city (Patrick, 2005; Steingrimsdottir et al., 2000).
It should be noted that all antiviral drug nucleoside 
analogues, such as gancyclovir and pencyclovir, that pre-
sent an open saccharide portion, require triphosphoryla-
tion in order to execute their antiviral function and thus are 
analog bioprecursors. In the same context, several antire-
troviral drugs (Figure 6) such as zidovudine, estavudine, 
didanosine, lamivudine, zalcitabine (Carneiro França, 
2008) and entricitabine, not yet available on the Brazilian 
market, that present a similar bioactivation mechanism, 
FIGURE 5 - Diagram of acyclovir bioactivation into acyclovir trisphosphate. GMP-guanosine monophosphate.
Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways 397
FIGURE 6 - Structures of bioprecursor-type antiviral prodrugs (ganciclovir and penciclovir) and antiretrovirals (zidovudine, 
estavudine, didanosine, emtricitabine, lamivudine, zalcitibine).
FIGURE 7 - The cholesterol biosynthetic pathway of HMGCo-A (hydroxy-methylglutaryl-Coenzyme A).
are considered bioprecursor prodrugs (De Clercq, 2002, 
2004; Otto, 2004).
Antilipemic Agents
Currently, high levels of cholesterol associated with 
other risk factors have led to serious repercussions in the 
quality of life of the world’s population. Thus, imminent 
risks regarding the development of cardiovascular diseases 
have aroused great interest on the part of the pharmaceu-
tical industries, resulting in the search for new therapeu-
tically useful agents. 
Statins (Carneiro França, 2008) are hypocholestero-
lemic drugs discovered in the 1970s that are currently the 
blockbusters of the pharmaceutical industry, topping one 
billion dollars in sales. Statins are capable of inhibiting 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCo-A 
reductase - HMGR), a fundamental enzyme in the cho-
lesterol biosynthetic pathway (Figure 7). This enzyme 
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presents hydroxy-methylglutaryl-Coenzyme A (HMGCo-
A) as a natural substrate. Upon acting on this substrate, 
HMGCo-A reductase converts it into mevalonic acid, one 
of the precursors of cholesterol synthesis (Mauro, 1993; 
Viegas-Junior et al., 2006).
The first statin to be isolated was mevastatin (Figure 
8), a substance extracted from the fungus Penicillium sp. 
Researchers in Sankyo (Japan) noted the similarity of the 
active metabolite of mevastatin to the natural substrate of 
the cholesterol biosynthetic pathway. The effectiveness of 
this metabolite can be explained by the structural similarity 
to the precursor of cholesterol, as indicated in Figure 8. 
Accordingly, mevastatin needs to be biotransfor-
med into its active form (acyclic derivative) to become 
active. Consequently, this compound is a bioprecursor, 
since lactone hydrolysis is required (function g-lactone-
β-hydroxylate) for its hypocholesterolemic function. The 
statins on the market, for example lovastatin and sinvasta-
tin (Figure 9), which present the g-lactone-β-hydroxylate 
function, are also bioprecursors. After being absorbed by 
FIGURE 8 - The structure of mevastatin, of its active metabolite and the similarity to the HMG-CoA reductase substrate 
(intermediary).
FIGURE 9 - Statins used in therapeutics.
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the intestine, lovastatin and sinvastatin are hydrolized and 
quickly converted into open hydroxy acids, which in turn 
correspond to the active metabolite (Roche, 2005).
On the other hand, pravastatin was the first statin 
to present an open lactone function and therefore it is not 
classified as a bioprecursor. For the same reason, fluvas-
tatin, atorvastatin and rosuvastatin are also not considered 
bioprecursors (Campo, Carvalho, 2007; Viegas-Junior et 
al., 2006).
Lovastatin was approved for clinical use in 1987 and 
after its introduction, other statins were launched on the 
market and since then these compounds have also been 
ranked as “blockbuster” drugs. Currently, it is estimated 
that the world pharmaceutical market generates about 700 
billion dollars a year, with the statin trade alone accounting 
for more than 15 billion dollars of this total (IMS, 2009; 
Viegas-Junior et al., 2006). This observation is an indica-
tion of the importance of latentiation of drugs in the world 
pharmaceutical market. 
Antiparkinsonian Agents
A classic example of a bioprecursor prodrug is levo-
dopa. This drug corresponds to the immediate dopamine 
precursor, although contrary to the latter, it is able to cross 
the blood-brain barrier. Levodopa has been used to treat 
Parkinson’s disease, a condition caused by deficiency in 
dopamine, which cannot be employed due to insufficient 
lipophilicity to cross the blood-brain barrier. However, 
levodopa is an even more polar structure compared to 
dopamine. Its amino acid characteristic enables it to use 
transporters of neutral amino acids (LAT1) present in the 
blood-brain barrier and accordingly, it can cross the cellu-
lar membrane. Subsequently, it undergoes decarboxylation 
through the action of the aromatic L-amino acid decarbo-
xylase, thus releasing dopamine (Figure 10) (Stefano et 
al., 2008; Bravo, Nassif, 2006). 
Antiulcerous agents 
The gastric H+/K+ ATPase pump inhibitors, also 
called proton pump inhibitors, consist of a group of drugs 
widely employed in the treatment of gastric ulcers. The 
enzyme is responsible for the production of acid in the 
stomach and is located in the apical membranes of the pa-
rietal cells. Over the last decade, these drugs have largely 
replaced H2 antihistamines, such as cimetidine, ranitidine 
and famotidine. The lowering of enzymatic activity leads 
to a reduction in the concentration of hydrogen ions (H+) in 
the stomach, thus increasing the stomach´s pH (Lindberg 
et al., 1986; Roche, 2006). 
The main inhibitors used in therapy in Brazil are 
omeprazole and its pure enantiomer, esomeprazole (S-
omeprazole), along with lansoprazole, pantoprazole 
and rabeprazole (Figure 11) (Carneiro França, 2008; 
Robinson, 2004).
All of these drugs are administered in their inactive 
form, becoming active under acidic conditions of the 
canaliculi of the gastric mucosa, as shown in Figure 12 
(Lindeberg et al., 1986). All members of this class are 
therefore considered to be bioprecursors (Barradell et al., 
1992; Shin et al., 2004).
Antineoplasic Agents
Cyclophosphamide is a synthetic bioprecursor anti-
neoplasic drug, belonging to the alkylating agents class of 
the nitrogen mustard group, that bonds covalently to DNA. 
This drug is inactive when tested in vitro on human lym-
phocyte cultures or on human neoplastic cells. However, 
in vivo, when converted to its active form by microsomal 
cells in the liver, it interferes with the growth of susceptible 
neoplastic tumors. 
The biological function of cyclophosphamide, as well 
as the other members of the nitrogen mustard group, is based 
on the presence of the bis-(2-chloroethyl) group. Cyclo-
phosphamide is hydroxylated in the liver by CYP4502B, and 
converted into 4-hydroxy-cyclophosphamide (Figure 13). 
This dependency on bioactivation by the CYP450 system is 
an advantage over other compounds of the nitrogen mustard 
group (Cohen, Jao, 1970). These are chemically unstable 
to varying degrees, with some reacting almost totally in the 
organism a few minutes after being administered, which 
can lead to high rates of toxicity (Griskevicius et al., 2003).
The 4-hydroxy-cyclophosphamide is found in dyna-
mic equilibrium with its acyclic tautomer, aldofosfamide. 
It can undergo two pathways of biotransformation, one 
enzymatic and the other non-enzymatic. Through the enzy-
matic pathway, it can be oxidized to aldehyde in the liver 
FIGURE 10 - Metabolic pathway for dopamine formation.
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or in the tumor and, perhaps by other enzymes, producing 
carboxy-phosphamide and 4-ceto-cyclophosphamide that 
have no significant biological activity. Through the non-
enzymatic pathway, aldofosfamide undergoes spontaneous 
cleavage, producing fosforamide mustard and acrolein, 
the former being responsible for antitumoral effects, and 
the latter for haemorrhagic cystitis observed after using 
cyclophosphamide. The fosforamide mustard engages 
DNA in the tumor cells, resulting in the cross-bonding of 
the nucleic acid chains or binding to a nucleic acid or a pro-
tein. Such alterations severely damage the DNA molecule, 
leading to the demise of the cell (Lemke, Williams, 2008; 
Rooney et al., 2004; Santos et al., 2007).Currently, besides 
cyclophosphamide, a derivative of this drug, ifosfamide, 
FIGURE 12 - Omeprazole activation mechanism and sequential inhibition of gastric H+/K+ ATPase.
FIGURE 11 - The main gastric H+/K+ ATPase inhibitors.
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FIGURE 13 - Diagram of cyclophosphamide bioactivation.
is employed in anticancer chemotherapy treatment. This 
drug also requires bioactivation, and is thus another exam-
ple of a bioprecursor prodrug (Lemke, Williams, 2008).
Classic prodrugs
Classic prodrugs are obtained from the binding of 
a matrix drug and an adequate transporter group throu-
gh a covalent hydrolysable bond. The purpose of these 
prodrugs is to improve physical-chemical properties and 
consequently, overall therapeutic effectiveness, with a 
reduction in toxicity, prolonged action and an increase in 
bioavailability or selectivity. They are normally inactive 
and need to undergo chemical or enzymatic hydrolysis, 
thus releasing the active portion. Therefore, they abide 
by the classical definition of latentiation (Beaumont et al., 
2003; Chung et al., 2005).
The main classic prodrugs available on the Brazilian 
market are listed below, divided according to the different 
therapeutic categories.
Antivirals
Valacyclovir (Carneiro França, 2008) is a classic 
prodrug of acyclovir (Figure 14) and is therefore active 
against the Herpes simplex (VHs) virus, types 1 and 2, 
and Varicella zoster (VVZ), Epstein Barr (VEB) virus 
and cytomegalovirus (CMV). This prodrug was obtained 
from the esterification reaction between acyclovir and the 
valine amino acid. 
Valacyclovir was designed to increase the bioavaila-
bility of acyclovir. Peptide transporters represent attractive 
groups for the development of prodrugs. Prodrugs that 
have amino acids as transport groups present three- to 
ten-fold greater passage through the membrane than the 
original drug. Thus, the greater absorption of valacyclovir 
compared to acyclovir is due to the presence of the amino 
acid (valine) (Ettmayer et al., 2004; Thomsen et al., 2003; 
Thomsen et al., 2004; Vabeno et al., 2004). The presence 
of valine enables the passage of the drug through membra-
nes by means of specific amino acid transporters (hPEPT 
1 and 2) (Andersen et al., 2006; Steingrimsdottir et al., 
2000; Steffansen et al., 2004; Sugawara et al., 2000). Upon 
absorption, orally ingested valacyclovir is converted into 
acyclovir by the action of esterases. The acyclovir, in turn, 
is affected by viral thymidine kinase, thus transforming 
into its active form, acyclovir monophosphate, and then 
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di and triphosphate, with 54% absolute bioavailability, 
compared to the 12-20% of acyclovir. The fact that the 
bioavailability of oral valacyclovir is considerably greater 
than that obtained from oral acyclovir results in the need 
for smaller daily doses (Guo et al., 1999; Han, Amidon, 
2000).
Fancyclovir (Carneiro França, 2008), the diacetate 
of pencyclovir, is classified as a classic prodrug (Figure 15), 
whose purpose is to increase bioavailability. Fancyclovir 
was acquired after the acetylation of the hydroxyl groups 
present in the “open sugar” of pencyclovir. This compound 
was developed to adjust the pharmacokinetic properties of 
pencyclovir, which has limited oral absorption (4% oral 
bioavailability) which is increased to 75% with fancyclo-
vir (Barreiro, Fraga, 2008; Simpson, Lyseng-Williamson, 
2006). After absorption, fancyclovir is biotransformed by 
esterases, and pencyclovir is released which is subsequently 
affected by viral thymidine kinase, and is hence transformed 
into its active form, pencyclovir triphosphate. 
Fosamprenavir is an antiretroviral drug belonging 
to the class of protease inhibitors. It inhibits this enzyme, 
preventing the breakdown of a polyprotein precursor into 
functional and structural proteins of HIV (Stella et al., 2007). 
Fosamprenavir is a prodrug of amprenavir (Figure 16). 
Fosamprenavir is a calcium phosphate ester of am-
prenavir. This prodrug was designed to optimize the use 
of amprenavir by reducing the heavy dosage regimen, 
which in turn significantly reduces the quantity of pills 
to be taken compared to amprenavir, and accordingly, 
minimizing collateral effects. Therapy with amprenavir 
requires the ingestion of eight capsules daily to reach the 
total dosage of 1200mg. In contrast, the use of its prodrug 
requires the administration of only two pills per day, 
containing a total of 1400mg. Fosamprenavir is a more 
hydrosoluble derivative (10 times more soluble in water), 
compared to amprenavir, facilitating its formulation and 
absorption. Upon oral administration, fosamprenavir is 
quick and almost completely hydrolyzed in amprenavir 
and inorganic phosphate. The conversion of fosamprena-
vir into amprenavir, as well as its absorption, takes place 
in the intestinal epithelium. Fosamprenavir was licensed 
for the treatment of AIDS in 2004 (Chapman et al., 2004; 
Wire et al., 2006).
Tenofovir disoproxil is a prodrug derived from 
tenofovir, an analog of monophosphorylated nucleoside, 
which acts by inhibiting reverse transcriptase, an important 
HIV enzyme capable of promoting the transcription of 
viral RNA into viral DNA (Chapman et al., 2003; Gallant, 
Deresinski, 2003). The prodrug tenofovir disoproxil fuma-
rate was designed as a solution to overcome the limited 
oral bioavailability of tenofovir. It is transformed into 
tenofovir upon absorption (Figure 17). The hydrolysis 
FIGURE 14 - Reaction illustrating the release of acyclovir from its prodrug.
FIGURE 15 - The bioactivation pathway of fancyclovir.
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FIGURE 16 - Fosamprenavir structure (prodrug) and its conversion into amprenavir.
of tenofovir disoproxil fumarate, promoted by esterases, 
stechiometrically generates four types of molecules: iso-
propanol, carbon dioxide, formaldehyde and tenofovir 
(Larsen et al., 2004).
Oseltamivir is an orally administered prodrug of 
proven efficacy in the treatment of infections caused by 
the Influenza A and B viruses. This prodrug is converted 
into carboxylate of oseltamivir (GS4071), its active form, 
by hepatic esterases (Figure 18). The active metabolite is 
a powerful and selective inhibitor of the neuraminidase 
enzyme, a glycoprotein present on the surface of the virus, 
essential for the release of viral particles recently formed 
from infected cells and for the later expansion of the in-
fecting virus in the organism. The prodrug was designed 
to improve the bioavailability of its precursor, GS4071. 
Considering that carboxylate is a very hydrosoluble che-
FIGURE 17 - Chemical and enzymatic hydrolysis of tenofovir disoproxil fumarate into its active component, tenofovir. 
mical entity, the masking of this group was promoted by 
the formation of an ethyl ester. Accordingly, oseltamivir 
presents greater lipophilicity and, consequently, greater 
bioavailability (Fatima et al., 2005; Finley et al., 1999; 
Hayden et al., 1999; He et al., 1999).
Cardiovascular agents
The angiotensin-converting enzyme inhibitors re-
present a fairly significant class of cardiovascular drugs. 
The introduction of this family of antihypertensive agents 
arose from the experimental work carried out by Sérgio 
Ferreira involving venom from the Bothrops jararaca 
snake (Ferreira, 1965). A peptide was identified in this ve-
nom that, when administered intravenously, was capable of 
preventing the conversion of angiotensin I into angiotensin 
II, through the inhibition of the angiotensin-converting en-
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zyme (ACE). Based on the recognition that ACE inhibition 
results in hypotensive activity, a series of powerful ACE 
inhibitors was developed, which are active upon oral admi-
nistration (Wermuth, 2006). Captopril, marketed under se-
veral pharmaceutical brandnames (Carneiro França, 2008) 
(Figure 19), was the first ACE inhibiting antihypertensive 
agent and is an example of a drug developed from rational 
drug design, supported by contributions from Brazilian 
researchers. Captopril presents satisfactory bioavailability, 
when administered orally. However, it is one of the ACE 
inhibiting drugs with the lowest half-lives, compared to 
others from the same class, for example, enalapril, be-
nazepril, quinapril, ramipril and fosinopril (Friedman, 
Amidon, 1989; Dhareshwar et al., 2007), all classified as 
prodrugs with greater advantages in terms of half-life and 
improved bioavailability (Figure 19).
Esterification of the ester group or etherification of 
the phosphate group leads not only to an increase in lipo-
solubility, but also minimizes the biotransformation that 
rapidly takes place in the carboxylic-free group (Beaumont 
et al., 2003). Thus, as intended, the bioavailability and the 
half-life of the prototype drugs are altered. 
Antibiotics
The antibiotics class includes a very wide range of 
prodrugs available for use in therapy, whether to increase 
bioavailability, reduce toxicity or even to solve organolep-
tic and pharma-technical issues (Chung, Ferreira, 1998).
Ampicillin is currently a fairly widely used antibiotic 
due to its broad spectrum bactericidal activity and reduced 
toxicity. However, its bioavailability, when ingested orally, 
is only 30% to 50%, due to its low absorption (Carneiro 
França, 2008). Thus, there is an interest in ampicillin pro-
drugs with more lipophilic transporters, and a subsequent 
increase in lipophilicity. Bacampicillin (Figure 20) is 
an example of a classic ampicillin prodrug, with greater 
bioavailability than the penicillin it is derived from. With 
bioavailability greater than 95%, bacampicillin is admi-
nistered in an average oral dose of 400mg and thus attains 
high plasmatic levels, 7 μg/ml, which is equivalent to 1000 
mg of ampicillin. This pharmacokinetic characteristic 
provides rapid and elevated plasmatic concentrations, two 
or three times greater than those attained from the same 
doses of ampicillin. Its plasmatic half-life is approxima-
tely 60 minutes in individuals with normal renal function. 
Furthermore, its binding with plasmatic proteins is very 
low (18%), maintaining a high concentration of free and 
therapeutically active ampicillin (Bergan, 1978; Bodin et 
al., 1975; Sjövall et al., 1978).
It is important to observe that the transporter bon-
ded to position 2 of the thiazolidine ring is a double ester. 
This characteristic means greater access of the enzyme to 
the ester further away from the ring, thus preventing any 
steric hindrance that could interfere with the release of 
the drug. The esterases cleave the ester bond and a spon-
taneous rearrangement releases ampicillin and aldehyde, 
as illustrated in Figure 20.
The cephalosporin class of antibiotics also includes 
several prodrugs. Those of third and fourth generations, 
in particular, are fairly hydrophilic drugs that include 
aminotiazol and methoxamine groups in their structure, 
which are responsible for their broad spectrum bactericidal 
activity and resistance to beta-lactamases, respectively. 
Despite these characteristics, the high hydrosolubility of 
these more recent generation of cephalosporins impairs 
gastro-intestinal absorption, making oral administration 
unfeasible (Patrick, 2005). This difficulty led to the design 
of new chemical entities with, simultaneously, oral absorp-
tion, broad spectrum bactericidal activity and resistance 
to beta-lactamases. Accordingly, new orally administered 
cephalosporin prodrugs have arisen based on dual-esters, 
such as cefuroxime axetil, cefpodoxime proxetil and 
cefetamet pivoxil (Fuchs, 2007; Stella et al., 2007). As 
with bacampicillin, these prodrugs, being more lipophilic, 
are administered orally and feature greater bioavailabi-
lity. After absorption, they initially undergo enzymatic 
hydrolysis, followed by a chemical rearrangement due to 
the electronic characteristics of the intermediary formed, 
thus releasing cephalosporin (Figures 21 and 22) (Ehrnebo 
et al., 1979; Perry, Brogden, 1996).
Chloramphenicol is an antibiotic that was isolated 
by Burkholde for the first time in 1947 from Streptomyces 
FIGURE 18 - The activation of olsetamivir into the active metabolite GS4071.
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FIGURE 19 - Angiotensin-converting enzyme (ACE) inhibiting prodrugs and their respective hydrolyses to their active forms
venezuelae. This compound was the first antibiotic effec-
tive against a wide variety of microorganisms to be used 
particularly in the treatment of serious infections such as 
typhoid fever and other forms of salmonellosis, Haemo-
philus Influenza infections, especially of the meninges, 
as well as other infections of the nervous system and 
respiratory tract (Carneiro França, 2008). However, it is 
associated with severe toxic side effects such as bone mar-
row depression, especially fatal aplastic anemia (Powell, 
Nahata, 1982).
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FIGURE 20 - Bacampicillin structure and its conversion into ampicillin.
FIGURE 21 - Cefuroxime axetil structure and its conversion into cefuroxime.
With the appearance of safer agents, chlorampheni-
col is frequently considered to be an antibiotic of purely 
historical interest. However, it is still useful in some situ-
ations, such as in seriously ill individuals for whom safer 
alternatives are less effective, or when such alternatives are 
not available. This drug has a bitter taste, which is difficult 
to mask in orally administered solutions. Researchers dis-
covered that the drug became flavorless when transformed 
in palmitic ester, due to the reduction of hydrosolubility 
(Figure 23). Chloramphenicol palmitate is a prodrug of 
cloramphenicol, obtained from the sterification reaction 
between the drug and palmitic acid. It is therefore inac-
tive, and for it to become active, it undergoes hydrolysis 
of the ester bond through the action of pancreatic lipases 
in the duodenum54. The acquired prodrug is a lipophilic 
compound, which means it can be marketed as an oral 
suspension (Bechelli, 2003; Carneiro França, 2008).
With the aim of acquiring a hydrosoluble pharma-
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FIGURE 22 - Cefpodoxime proxetil and cefetamet pivoxil structures being bioactivated into cefpodoxime and cefetamet, 
respectively.
FIGURE 23 - Enzymatic conversion of the chloramphenicol palmitate into chloramphenicol, its active form.
ceutical form for ophthalmic application, chloramphenicol 
has also been transformed into succinic hemiester (Figure 
24), which, through hydrolysis, releases the antibiotic 
locally (Carneiro França, 2008). 
Erythromycin (Figure 25) is a macrolide antibiotic, 
structurally characterized by the presence of a 14-atom lac-
tone, to which two sugars are bonded. One of these sugars 
features an amino group, giving the drug the characteristic 
of a weak base that enables the formation of salts with orga-
nic acids (Lemke, Williams, 2008). It is a drug that is effec-
tive against a wide variety of microorganisms. However, its 
bitter taste and instability in an acidic medium prevented its 
therapeutic use. In an attempt to solve these limitations, its 
derivatives, erythromycin stearate and erythromycin esto-
late, are used for therapy in Brazil (Carneiro França, 2008; 
Tavares, 2001). Erythromycin stearate is a salt capable of 
reducing the bitterness and, especially, increasing stability 
in an acidic medium. The lauryl sulfate salt of propionyl 
erythromycin ester, more commonly known as erythromy-
cin estolate, is the prodrug available in Brazil (Carneiro 
França, 2008; Tavares, 2001). This prodrug is obtained 
from the sterification reaction between the hydroxyl group 
of amino sugar present in erythromycin and propionic acid 
carboxyl group, which acts as a transporter group. Sterifi-
cation reduces the bitterness of erythromycin and increases 
its oral absorption, releasing free erythromycin into the 
bloodstream or muscle tissue after the action of esterases. 
Data from literature indicates that erythromycin estolate is 
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capable of producing more elevated and prolonged serum 
levels than other salts due to the greater absorption rate of 
esters (Lemke, Williams, 2008; Tavares, 2001). Figure 25 
illustrates the structures of erythromycin, erythromycin 
stearate and erythromycin estolate.
Antipsychotics 
Antipsychotics are drugs used for the treatment of 
schizophrenia. In some circumstances, orally administe-
red medicine regimens are not suitable for schizophrenic 
patients and the administration of long-acting prodrugs by 
intramuscular injection is recommended. This is the safest 
means of maintaining clinical stability and preventing relap-
ses. In Table 1, several long-acting antipsychotics are listed. 
For instance, fluphenazine enanthate, haloperidol decano-
ate, zuclopenthixol decanoate and pipothiazine palmitate 
are available on the Brazilian market (Carneiro França, 
2008). All are administered by intramuscular injection and 
obtained through sterification reaction between the drugs 
and long-chain carboxylic acids, which confer a high rate of 
liposolubility on the resulting derivatives (Bechelli, 2003).
Fluphenazine decanoate (piperazine phenothiazine) 
and haloperidol decanoate (butyrophenone) are prodrugs 
administered in an oil-based depot injection, where the 
agent is stored in the adipose tissue and then gradually 
released into the organism over a long period of time. After 
deep intramuscular injection, fluphenazine decanoate and 
haloperidol decanoate spread slowly and are hydrolyzed 
into their active forms fluphenazine and haloperidol, res-
pectively, which then cross the blood-brain barrier (Figu-
re 26). It is possible to obtain a stable serum concentration 
from the drugs for nearly four weeks after an initial peak, 
and half-life is in the range of 2.5 to 16 weeks (Beresford, 
Ward, 1987; Jann et al., 1985).
Steroid hormones
One of the strategies for extending the period of 
action is to design prodrugs with increased lipophilicity, 
thus obtaining depot forms whose drugs are gradually re-
lease into the organism (Batres et al., 1956). This strategy 
can be observed in the development of sexual hormones 
with long-acting release during contraceptive therapy, 
hormonal replacement therapy or pregnancy (Petrow, 
1970; Ghiselli, Jardim, 2007). The use of prodrug steroid 
hormones in therapy may also be applied to compounds 
that can be administered orally, thus increasing the absorp-
tion of the hormones. This design involves the binding of 
the hormone to a transporter group, generally masking a 
hydrophilic functional group, through an ester bond which 
increases lipophilicity and leads to derivatives for oral or 
parenteral administration. The extension of the period of 
action of these steroid hormones derived from parenterally 
FIGURE 24 - Bioactivation of chloramphenicol succinate. 
FIGURE 25 - Conversion of erythromycin stearate and erythromycin estolate into erythromycin.
Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways 409
administered esters can be explained by the slow absorp-
tion from the site of administration or by the resistance to 
biotransformation (Biagi et al., 1975). 
A practical and long-acting form of contraception is 
the use of injectable progesterone prodrugs, providing 2-4 
months of contraception. There are also monthly injections, 
which are combinations of estrogen and progesterone 
prodrugs, administered in intramuscular injections once a 
month (Araújo-Junior, Athanazio, 2007). The structures of 
steroid hormone prodrugs, as well as their release to active 
form, are illustrated in Figure 27. The main compounds 
include (Carneiro França, 2008): medroxyprogesterone 
acetate, hydroxyprogesterone caproate, algestone ace-
tophenide (long-acting progestogens), estradiol valerate 
TABLE I - Long-acting antipsychotics
PRODRUGS ADMINISTRATION INTERVAL (WEEKS)
BROMPERIDOL (DECANOATE) 4 
CLOPENTIXOL (DECANOATE) 3 to 4 
FLUPHENAZINE (DECANOATE) 2 to 3 
FLUPHENAZINE (ENANTHATE) 2 
HALOPERIDOL (DECANOATE) 4 
PERPHENAZINE (DECANOATE) 3 to 4 
PERPHENAZINE (ENANTHATE) 2 
PIPOTHIAZINE (PALMITATE) 2 
PIPOTHIAZINE (UNDECYLENATE) 4 
ZUCLOPENTIXOL (DECANOATE) 2 to 4
FIGURE 26 - Release of haloperidol and fluphenazine from their respective prodrugs.
and estradiol enanthate (estrogenic prodrugs) (Aguilar et 
al., 1997; Mishell, 1996; Pasqualini, 1996).
Anti-asthmatic agents
Bambuterol is a prodrug of long-acting terbutaline, 
with an effective duration of 24 hours, thus able to be 
administered once a day. Bambuterol features catecholic 
hydroxyls (susceptible to pre-systemic metabolism). The 
fact that this type of bond is relatively resistant to hydroly-
sis explains the longer action of bambuterol. Terbutaline is 
an adrenergic agonist, which predominantly stimulates the 
beta-2 receptors, thus producing relaxation of the smooth 
muscle of the bronchus. After being absorbed, bambute-
rol undergoes a slow biotransformation, as indicated in 
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Figure 28, through hydrolytic and oxidation metabolic 
conversion, in order to form terbutaline. The maximum 
plasmatic concentration (Cmax) of the active metabolite 
(terbutaline) is reached in approximately 2-6 hours and it 
lasts at least 24 hours (Rautio et al., 2008; Rosenborg et 
al., 2001; Testa, 2004; Tunek, Svensson, 1988).
Antiglaucoma agents
Dipivefrin, derived from epinephrin is recommen-
FIGURE 27 - The main sexual hormones available on the market and their bioactivation.
ded for the treatment of ocular hypertension in open-
angle chronic glaucoma, and it functions by reducing the 
production of aqueous humor (Carneiro França, 2008). 
Dipivefrin is a prodrug of epinephrin obtained from the 
sterification of the catecholic hydroxyl groups present in 
epinephrin with pivalic acid. This sterification leads to an 
increase in lipophilicity and as a consequence, this prodrug 
is capable of permeating the corneal extract 17 times faster 
than epinephrin. After absorption, hydrolysis of the esters 
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takes place, releasing the epinephrin (Figure 29) (Rautio et 
al., 2008; Mandell et al., 1978; Wei et al., 1978).
Mixed prodrugs used in therapy
Mixed prodrugs are latent forms with the simulta-
neous characteristics of bioprecursors and classic prodru-
gs. In other words, they present as biologically inactive 
molecules that need to undergo several chemical reactions 
(hydrolytic and/or oxyreductive) in order to be converted 
into their active forms (Bodor, Abdelalim, 1985; Chung 
et al., 2005;).
Antineoplasic agents
Capecitabine is a carbamoyl fluoropyrimidine 
with an antineoplasic function, which features reduced 
gastrointestinal toxicity and high tumor selectivity. It is 
a prodrug that, after three stages of biotransformation 
(Figure 30), creates fluorouracil, a compound with an 
antineoplasic function. It is quickly absorbed by the 
gastrointestinal system, initially undergoing hepatic bio-
activation by carboxylic esterase, thus forming 5’-deoxy-
5-fluorocytidine. Cytidine deaminase, an enzyme found 
in several types of tissue, including tumors, subsequently 
converts 5’-deoxy-5-fluorocytidine into 5’-deoxy-5-
fluorouridine. The enzyme thymidine phosphorylase then 
converts 5’-deoxy-5-fluorouridine into the active drug flu-
orouracil. Many tissues throughout the organism contain 
thymidine phosphorylase. Some human carcinomas have 
high concentrations of this enzyme, a fact that favors the 
high rate of specificity of this drug (Miwa, 1998; Quinney 
et al., 2005; Schuller et al., 2000; Tabata et al., 2004).
Reciprocal prodrugs 
Despite the fact that the classic concept of latentiation 
refers to compounds containing pharmacologically inactive 
transporter groups, this cannot be extended to what is ter-
med the reciprocal prodrug. In this type of derivative the 
transporter also has a therapeutic function, as it is consti-
tuted from the chemical association between two drugs, in 
such a manner that one acts as the transporter for the other, 
thus improving the effect of both. From their development, 
it is possible to obtain prodrugs with different or similar 
FIGURE 28 - Hydrolytic and oxidation metabolic conversion of bambuterol into terbutaline.
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FIGURE 29 - Enzymatic conversion of dipivefrin into its active metabolite, epinephrin
therapeutic functions, acting through distinctive or equal 
mechanisms of action (Chung et al., 2005; Chung, Ferreira, 
1998; Silva et al., 2005; Singh, Sharma, 1994).
Reciprocal prodrugs differ from molecular hybrids 
(Barreiro, Fraga, 2008) because the former must be released 
through bond cleavage to perform its therapeutic effect. 
Antibacterial agents
Sulfasalazine, introduced in 1942, is a highly useful 
prodrug, and one of the few available for the treatment of 
several types of chronic inflammatory intestinal diseases 
and rheumatoid arthritis. Through the action of intestinal 
azoreductases, this prodrug (Figure 31) releases, in vivo, 
two pharmacologically active substances, sulfapyridine 
and 5-aminosalicylic acid (5-ASA) (Chung et al., 2005; 
FIGURE 30 - Diagram of the metabolic bioactivation of capecitabine.
FIGURE 31 - Diagram of the bioactivation of sulfasalazine 
through the action of azoreductases.
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Freire et al., 2006; Singh, Sharma, 1994). 5-ASA is the 
effective component in diseases of the colon, however, 
after oral administration it undergoes intense absorption 
in the upper parts of the gastrointestinal tract, and is not 
locally effective on the colon (Dash, Brittain, 1998). In 
fact, when administered in sulfasalazine form, at least 85% 
of an oral dose passes intact through the stomach and small 
intestine (Watts, Illum, 1997). 
In 1960, the idea of synthesizing antibacterial drugs 
with dual-function arose, by employing the reciprocal 
prodrug concept. One of the first attempts at producing 
dual-function antibacterial drugs involved binding of the 
central nucleus of penicillin (6-APA) with norfloxacin, 
with the aim of providing more powerful antibacterial 
agents and two mechanisms with several functions. 
Later, prodrugs from cephalosporins with wide-ranging 
fluoroquinolones were obtained. The most efficient bi-
functional derivative obtained consisted of the union 
between fleroxacin and cefotaxine (Figure 32). This 
compound, called Ro-239424, featured a broad range 
of effectiveness and a dual-function mechanism, i.e., 
it possessed effectiveness against transpeptidase and 
bacterial DNA gyrase, due to the beta-lactams and the 
fluroquinolonic portions of the molecule, respectively. 
This compound, however, is not yet available for use in 
therapy (Bhanot et al., 2001). 
Sultamiciline is an example of a reciprocal prodrug 
used in therapy. It consists of a dual ester obtained from 
the bond between ampicillin and sulbactam, a non-classic 
beta-lactams antibiotic. Besides masking the free carbo-
xylic acid present in the structure of these compounds, 
thus facilitating absorption, this union is an advantage, 
because ampicillin is active in oral administration but 
inactive with beta-lactamases, while the latter is just a 
beta-lactamase inhibitor. After the absorption of the sul-
tamicilin, hydrolysis of the esters takes place (Figure 33) 
which releases ampicillin with antibacterial function and 
sulbactam, capable of binding to beta-lactamase enzymes. 
This protects classic penicillin from beta-lactamase action. 
Sultamiciline is recommended for infections caused by 
microorganisms sensitive to the combination of ampi-
cillin and sulbactam (Carneiro França, 2008). Typical 
recommendations are: infections of the upper and lower 
respiratory tracts, including sinusitis, otitis media and 
epiglotitis; bacterial pneumonia; infections of the urinary 
tract and pyelonephritis; intra-abdominal infections, in-
cluding peritonitis, cholecystitis, endometritis and pelvic 
cellulitis; bacterial sepsis; skin, soft tissue, bone and joint 
infections, as well as gonococcal infections (Friedel et al., 
1989; Lopez, Rivas, 1998).
CONCLUSION
Latentiation can be considered a tool of Pharma-
ceutical Chemistry that enables, in a simple fashion, im-
provement of the physical-chemical properties of drugs, 
adapting their pharmaceutical and/or pharmacokinetic 
characteristics, thus allowing the introduction, re-intro-
duction or simple optimization of drugs used in therapy.
Through data found in literature, we observed that 
most prodrugs available for use in therapy are classic pro-
drugs, making up 53% of the total analyzed, followed by 
bioprecursors, with 42% market share. Regarding classic 
FIGURE 32 - Example of a reciprocal prodrug between fleroxacin and cefotaxine. 
FIGURE 33 - Diagram of bioactivation of the sultamiciline 
prodrug.
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prodrugs, despite the possibility of designing different 
types of hydrolysable bonds between the drug and the 
transporter group, it was observed that most of the agents 
available for use in therapy are of an ester-type bond, 
which is easily hydrolyzed within the organism. The main 
purpose of these ester derivatives is to increase bioavai-
lability and to extend the period of effectiveness. Despite 
the first reciprocal prodrug compound (sulfasalazine) 
having been introduced into therapy in 1942, not many 
examples of this type of prodrug are found in clinics. On 
the other hand, proposals for several reciprocal prodrugs 
were observed in different lines of research.
From the results obtained, it was evident that the 
number of prodrugs introduced onto the market has in-
creased. For example, of all the medicine approved in 
2001-02, prodrugs accounted for 15% (Stella, 2004). On 
the other hand, it is important to emphasize the importance 
of the therapeutic significance of existing prodrugs. Seve-
ral classes of drugs considered to be “blockbusters”, that 
is top-selling drugs, such as statins, antiulcerous agents, 
anti-hypertensive agents and antivirals feature some 
examples that are prodrugs, for example, sinvastatin (a 
hypocholesterolemic agent), omeprazol (an antiulcerous 
agent), enalapril (an anti-hypertensive ECA inhibitor) and 
acyclovir (an antiviral), respectively.
It has been further observed that antineoplasic pro-
drugs on the market are classified as either bioprecursors or 
mixed prodrugs. Despite featuring a lower level of toxicity 
compared to other antineoplasic agents of the same class, 
latentiation of drugs should be examined further for the 
acquisition of antineoplasic agents with greater selectivity 
and lower toxicity. In addition, it is important to emphasize 
that there is some research directed towards the acquisition 
of antineoplasic prodrugs using, for example, peptides 
as transporters or more advanced techniques, known as 
ADEPT (Antibody-Directed Enzyme Prodrug Therapy) 
or GDEPT/VDEPT (GeneVirus-Directed Enzyme Prodrug 
Therapy) (Chung et al., 2005), for which, derivatives have 
not yet been used in therapy.
Although several types of prodrugs from very 
distinctive classes are available for use in therapy, it can 
be noted that none of those mentioned are used for the 
treatment of neglected illnesses. However, latentiation 
should be explored when designing chemical entities for 
tropical endemic diseases, since it is not a costly method 
and has the potential of giving rise to therapeutically useful 
compounds.
Several prodrugs for the therapeutic treatment of 
these diseases have already been proposed and synthesi-
zed (Chung et al., 2005). In most cases, such compounds 
aim to increase selectivity. In 1996, for example, Chung, 
1996, synthesized reciprocal prodrugs from primaquine 
and nitrofural (Chung et al., 2000),using dipeptidyl spa-
cers with a scission selected by cruzipain (the exclusive 
enzyme of T. Cruzi), the purpose being to obtain potential 
drugs to combat American trypanosomiasis. The derivati-
ve hydroxymethylnitrofural has proven to be more active 
and less toxic than its prototype (Chung et al., 2003) and 
despite the mechanism still not having been fully unders-
tood, several aspects of it are being studied (Barbosa et 
al., 2007; Doriguetto et al., 2005; Guido et al., 2001a; 
Guido et al., 2001b; Grillo et al., 2007; Grillo et al., 
2008a; Grillo et al., 2008b; Melo et al., 2007; Trossini, 
2008). On the other hand, Parise-Filho et al. (2004, 2007) 
and Parise-Filho and Silveira (2001) proposed polymeric 
prodrugs from oxamniquine with the aim of extending its 
period of effectiveness and reducing the toxicity of this 
schistosomal agent. 
Many studies and research projects are being carried 
out in an effort to design new prodrugs which open up 
new perspectives for the treatment of several diseases. 
However, the aim of the present study was only to pre-
sent existing prodrugs used in therapy, confirming the 
importance of this method not only as a research tool. It 
was ascertained that, although current research on the la-
tentiation of drugs explores more advanced technologies, 
the prodrugs available for therapy to date have mostly been 
based on simpler design strategies.
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